Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared on LinkedIn:
“Hot off the press!
Delighted to share with the world my commentary in the journal Nature Communications perfectly timed for American Society of Clinical Oncology (ASCO) annual meeting!
“Tissue-agnostic cancer therapies: promise, reality, and the path forward”
Diving deep into where we are and where we’re headed with these treatments.
What’s your take on molecular vs. anatomical cancer classification? Drop your thoughts below!
Open access free link.”
You can find more posts featuring Vivek Subbiah on OncoDaily.